Teprotumumab (Tepezza)
Thyroid Eye Disease (TED)
ApprovedCommercial
Key Facts
About XOMA
XOMA has strategically transformed from a traditional drug developer into a capital-efficient royalty aggregator, building a diversified portfolio of economic interests in innovative therapeutic candidates. The company's model mitigates traditional biotech risks by acquiring rights to potential future payments from partnered programs, many of which are advanced by well-funded biopharma partners. XOMA's deep expertise in antibody science informs its investment decisions, targeting programs with validated biology and significant commercial potential across various therapeutic areas.
View full company profileTherapeutic Areas
Other Thyroid Eye Disease (TED) Drugs
| Drug | Company | Phase |
|---|---|---|
| VRDN-001 | Viridian Therapeutics | Phase 3 |
| VRDN-002 | Viridian Therapeutics | Phase 1/2 |
| YB-101 (GS-098) | Vyne Therapeutics | Phase 1 |